Johnson & Johnson announced sales of $17.5 billion for the first quarter of 2013, an increase of 8.5% as compared to the first quarter of 2012. Operational results increased 9.8% and the negative impact of currency was 1.3%. Domestic sales increased 11.2%. International sales increased 6.3%, reflecting operational growth of 8.7% and a negative currency impact of 2.4%.
“We delivered solid first quarter results led by the success of many of our recently launched pharmaceutical products and the addition of Synthes to our orthopaedics business. Also of note is the growth in our over-the-counter medicines business as we continue to make progress in returning a reliable supply of high quality products to our customers,” said Alex Gorsky, chairman and CEO of Johnson & Johnson. “Our investments to advance our pipelines and expand our global presence, along with the outstanding efforts of our talented people, will enable us to continue to deliver sustainable growth and meaningful innovations to patients and customers around the world.” The company confirmed its earnings guidance for full-year 2013 to $5.35–5.45 per share, and this excludes the impact of special items.
For its worldwide consumer division, J&J recorded sales of $3.7 billion for the first quarter, which represented an increase of 2.2% versus the prior year consisting of an operational increase of 3.3% and a negative impact from currency of 1.1%. Domestic sales increased 2.4%, and international sales increased 2.1%, which reflected an operational increase of 3.8% and a negative currency impact of 1.7%. Positive contributors to operational results for the division included Listerine mouthwash and Neutrogena skin care products. Also during the quarter, Johnson & Johnson (China) Investment Co., Ltd. completed the acquisition of Shanghai Elsker Mother & Baby Co., Ltd, a well-regarded baby care company in China known for its position in the naturals segment.
Additional details on J&J’s Q1 2013 financial report can be found here.
